CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Cash Flows from Operating Activities:
Net income	$ 109,698	$ 97,191
Non-cash items:
Depreciation and amortization	87,378	69,576
Amortization of fair value inventory step-up	12,319	0
Share-based compensation expense	22,699	20,912
Impairment of intangible assets	2,391	10,419
Gain on repurchase of convertible senior notes, net	(12,600)	0
Inventory reserve adjustment	1,289	6,904
Gains on sales of property, plant and equipment	(14,572)	(647)
Deferred tax benefit	(8,593)	(5,138)
Other non-cash operating activities	8,114	5,748
Change in operating assets and liabilities:
Change in accounts receivable	(3,379)	(27,743)
Change in inventories	(65,629)	(40,721)
Change in prepaid income taxes	(2,638)	1,730
Change in other assets and other liabilities	(34,493)	(15,619)
Change in accounts payable and accrued expenses	(36,816)	(4,942)
Net cash provided by operating activities	65,168	117,670
Cash Flows from Investing Activities:
Capital expenditures	(23,635)	(31,440)
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment	(12,649)	(25,171)
Acquisition, net of cash acquired	(150,906)	(243,852)
Proceeds from sale of property, plant and equipment	20,802	1,259
Other investing activities	(13,547)	(10,129)
Net cash used in investing activities	(179,935)	(309,333)
Cash Flows from Financing Activities:
Proceeds from issuance of convertible notes	700,000	0
Repurchase of convertible senior notes	(185,500)	0
Purchase of capped call related to convertible notes	(88,200)	0
Term loan borrowings	250,000	0
Term loan redemption	(262,500)	0
Proceeds from revolving facility	0	110,000
Payments on revolving facility	50,000	0
Repayment of term loan borrowings	(3,125)	(8,750)
Debt issuance costs	(23,135)	0
Share repurchases	(75,000)	0
Proceeds from employee stock purchase plan	6,476	5,603
Proceeds from exercise of stock options	1,717	1,505
Cash used to net share settle employee equity awards	(10,243)	(5,885)
Other financing activities	(222)	(814)
Net cash provided by financing activities	260,268	101,659
Effect of exchange rates on cash and cash equivalents	(3,455)	(484)
Net Change in Cash and Cash Equivalents	142,046	(90,488)
Cash and Cash Equivalents at Beginning of Period	178,800	284,466
Cash and Cash Equivalents at End of Period	$ 320,846	$ 193,978